Close Menu

NEW YOK (GenomeWeb) – Caris Life Sciences said today that it has raised $150 million in growth capital through senior secured debt and convertible notes from TPG Sixth Street Partners (TSSP).

The Irving, Texas-based company said it intends to use the proceeds to launch new cancer profiling services, expand its commercial organization, increase the capacity of its clinical and R&D laboratory, grow the capabilities of its biopharmaceutical business, enforce its patents, and pursue other strategic corporate initiatives.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.

May
27
Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments. 

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.